Anti Inflammatory Treatment of Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Levamlodipine
Amlodipine
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Levamlodipine, Amlodipine, Serum inflammatory factors, Anti inflammatory treatment
Eligibility Criteria
Inclusion Criteria:
- ① In line with the diagnostic criteria of ISH2020 International Guidelines for Practice of Hypertension ② Age >18 years old, gender is not limited, during the treatment did not take other drugs that will affect blood pressure: such as antidepressants, oral contraceptives, Chinese herbal medicine, etc.; Voluntary participation and signing of informed consent, and can complete all the visit plan.
Exclusion Criteria:
- (1) Those who do not want to take blood tests; (2) Left ventricular ejection fraction < 50%, heart rate <50 beats/min; ③ Acute coronary syndrome (unstable angina pectoris and myocardial infarction); ④ valvular heart disease, congenital heart disease, etc.; Other infectious diseases and malignant tumors; ⑥ Bronchial asthma; ⑦ Abnormal liver function and renal dysfunction (ALT BBB 0 80U/L, CR BBB 1 442mmol/L); Autoimmune diseases or any serious and fatal diseases; ⑨ Receiving lipid-lowering therapy and oral vitamins or antioxidants; They are mentally ill, have no self-awareness, and are unable to express themselves or cooperate with others.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Levamlodipine group
Amlodipine group
Arm Description
Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate
To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate
Outcomes
Primary Outcome Measures
After treatment, the blood pressure control of L-amlodipine group was better than that of amlodipine group
the serum inflammatory factor level of L-amlodipine group was lower than that of amlodipine group
Serum ATP level can be used to evaluate the anti-inflammatory effect of hypertension drugs
Secondary Outcome Measures
Full Information
NCT ID
NCT04740840
First Posted
February 4, 2021
Last Updated
February 4, 2021
Sponsor
Affiliated Hospital of North Sichuan Medical College
Collaborators
First Hospitals affiliated to the China PLA General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04740840
Brief Title
Anti Inflammatory Treatment of Hypertension
Official Title
Comparison of Anti-inflammatory Effects of Amlodipine and Levamlodipine in Patients With Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
May 1, 2010 (Actual)
Primary Completion Date
April 2, 2012 (Actual)
Study Completion Date
May 2, 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Affiliated Hospital of North Sichuan Medical College
Collaborators
First Hospitals affiliated to the China PLA General Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To investigate the anti-inflammatory effect of amlodipine and levamlodipine in the treatment of hypertension
Detailed Description
A total of 200 inpatients or outpatients in the Department of cardiovascular medicine of the third people's Hospital of Mianyang City from April 2021 to October 2021, who met the diagnostic criteria of ish2020 international hypertension practice guidelines, were selected and randomly divided into control group and experimental group, with 100 cases in each group. The control group was treated with amlodipine and the experimental group was treated with levoamlodipine. The changes of blood pressure and serum inflammatory factors were observed before and after treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Levamlodipine, Amlodipine, Serum inflammatory factors, Anti inflammatory treatment
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Levamlodipine group
Arm Type
Experimental
Arm Description
Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate
Arm Title
Amlodipine group
Arm Type
Sham Comparator
Arm Description
To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate
Intervention Type
Drug
Intervention Name(s)
Levamlodipine
Intervention Description
According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Intervention Description
According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
Primary Outcome Measure Information:
Title
After treatment, the blood pressure control of L-amlodipine group was better than that of amlodipine group
Time Frame
One month after treatment
Title
the serum inflammatory factor level of L-amlodipine group was lower than that of amlodipine group
Time Frame
One month after treatment
Title
Serum ATP level can be used to evaluate the anti-inflammatory effect of hypertension drugs
Time Frame
One month after treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
① In line with the diagnostic criteria of ISH2020 International Guidelines for Practice of Hypertension ② Age >18 years old, gender is not limited, during the treatment did not take other drugs that will affect blood pressure: such as antidepressants, oral contraceptives, Chinese herbal medicine, etc.; Voluntary participation and signing of informed consent, and can complete all the visit plan.
Exclusion Criteria:
(1) Those who do not want to take blood tests; (2) Left ventricular ejection fraction < 50%, heart rate <50 beats/min; ③ Acute coronary syndrome (unstable angina pectoris and myocardial infarction); ④ valvular heart disease, congenital heart disease, etc.; Other infectious diseases and malignant tumors; ⑥ Bronchial asthma; ⑦ Abnormal liver function and renal dysfunction (ALT BBB 0 80U/L, CR BBB 1 442mmol/L); Autoimmune diseases or any serious and fatal diseases; ⑨ Receiving lipid-lowering therapy and oral vitamins or antioxidants; They are mentally ill, have no self-awareness, and are unable to express themselves or cooperate with others.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Anti Inflammatory Treatment of Hypertension
We'll reach out to this number within 24 hrs